IMPC phenotypes (gene matching)
B6.129P2-Pik3cbtm1(lacz-D931A)Bvan/Cnbc
| Status | Available to order |
| EMMA ID | EM:11632 |
| Citation information | RRID:IMSR_EM:11632 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6.129P2-Pik3cbtm1(lacz-D931A)Bvan/Cnbc |
| Alternative name | p110beta PI3K-D931A-LacZ |
| Strain type | Targeted Mutant Strains : Knock-in |
| Allele/Transgene symbol | Pik3cbtm1(lacz-D931A)Bvan |
| Gene/Transgene symbol | Pik3cb |
Information from provider
| Provider | Bart Vanhaesebroeck |
| Provider affiliation | UCL Cancer Institute, University College London |
| Additional owner | the University of Edinburgh |
| Genetic information | An IRES-lacZ-MC1-neo marker/selection cassette, flanked by loxP sites, was inserted after the STOP codon in the last exon (24) of Pik3cb/p110beta PI3K. Knock-in with lacZ cassette. |
| Phenotypic information | Homozygous:Have not been characterised in detail as homo- or heterozygous express lacZ under the control of the Pik3cb/p110beta PI3K promotor.Heterozygous:Mice show reduced phenotypes of homozygous. LacZ expression is reduced compared with homozygotes. |
| Breeding history | Backcrossed onto C57BL/6J for more than 10 generations. |
| References | None available |
| Homozygous fertile | females only |
| Homozygous viable | not known |
| Homozygous matings required | no |
| Immunocompromised | not known |
Information from EMMA
| Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
| Animals used for archiving | heterozygous C57BL/6OlaHsd males |
Disease and phenotype information
MGI phenotypes (gene matching)
- decreased body weight / MGI
- weight loss / MGI
- decreased embryo size / MGI
- postnatal growth retardation / MGI
- decreased circulating triglyceride level / MGI
- increased insulin secretion / MGI
- abnormal gluconeogenesis / MGI
- decreased lumbar vertebrae number / MGI
- decreased circulating cholesterol level / MGI
- insulin resistance / MGI
- decreased heart rate / MGI
- decreased glycogen level / MGI
- abnormal platelet physiology / MGI
- pancreatic islet hyperplasia / MGI
- decreased circulating creatinine level / MGI
- increased circulating glucose level / MGI
- increased mean corpuscular hemoglobin / MGI
- increased hemoglobin content / MGI
- increased lung weight / MGI
- pulmonary fibrosis / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- decreased platelet aggregation / MGI
- decreased birth body size / MGI
- decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
- embryonic lethality between somite formation and embryo turning, complete penetrance / MGI
- preweaning lethality, complete penetrance / MGI
- embryonic lethality, incomplete penetrance / MGI
- embryonic lethality before implantation, incomplete penetrance / MGI
- embryonic lethality during organogenesis, incomplete penetrance / MGI
- lethality throughout fetal growth and development, incomplete penetrance / MGI
- decreased fibroblast proliferation / MGI